ART With DTG Plus 3TC May Be Robust Switch Option For Virologically Suppressed Adults With HIV Infection And No History Of Virologic Failure, Study Shows

Infectious Disease Advisor (8/5, Nye) reports, “Antiretroviral therapy (ART) with dolutegravir (DTG) plus lamivudine (3TC) may be a robust switch option for virologically suppressed adults with HIV infection and no history of virologic failure, according to” a study. Researchers came to this conclusion after pooling data from the TANGO and SALSA trials, with the primary endpoint being “the rate of patients without virologic suppression (HIV RNA, ≥50 copies/mL) at 48 weeks in those who switched to DTG/3TC (n=615) vs continued their ART regimen (n=619).” The findings were published in Open Forum Infectious Diseases.